ADMET and Solubility Analysis of New 5-Nitroisatine-Based Inhibitors of CDK2 Enzymes

The development of new substances with the ability to interact with a biological target is only the first stage in the process of the creation of new drugs. The 5-nitroisatin derivatives considered in this study are new inhibitors of cyclin-dependent kinase 2 (CDK2) intended for anticancer therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Czeleń, Przemysław, Jeliński, Tomasz, Skotnicka, Agnieszka, Szefler, Beata, Szupryczyński, Kamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669656/
https://www.ncbi.nlm.nih.gov/pubmed/38002019
http://dx.doi.org/10.3390/biomedicines11113019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669656/
https://www.ncbi.nlm.nih.gov/pubmed/38002019
http://dx.doi.org/10.3390/biomedicines11113019

Ejemplares similares